Atlas Trials

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Clinical trial NCT07570979 · RECRUITING

Trial details

NCT number
NCT07570979
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Start date
2026-05-25
Primary completion
2030-06-03
Enrollment
208

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.